Counterpoint: There is a best duration of deep molecular response for treatment‐free remission, but it is patient‐specific, and that is the challenge-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Counterpoint: There is a best duration of deep molecular response for treatment‐free remission, but it is patient‐specific, and that is the challenge

Published:2020-11-10 Issue:1 Volume:192 Page:24-27
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Ross David M.¹²³⁴^ORCID,Hughes Timothy P.¹²³^ORCID

Affiliation:

1. Precision Medicine Theme South Australian Health & Medical Research Institute AdelaideAustralia

2. Department of Haematology Royal Adelaide Hospital AdelaideAustralia

3. School of Medicine University of Adelaide AdelaideAustralia

4. Flinders University and Medical Centre Adelaide Australia

Funder

Cancer Council South Australia

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.17111

Reference37 articles.

1. Treatment-free remission after first-line dasatinib discontinuation in patients with chronic myeloid leukaemia (first-line DADI trial): a single-arm, multicentre, phase 2 trial

2. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial

3. Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study

4. Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom study

5. Loss of Major Molecular Response As a Trigger for Restarting Tyrosine Kinase Inhibitor Therapy in Patients With Chronic-Phase Chronic Myelogenous Leukemia Who Have Stopped Imatinib After Durable Undetectable Disease

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Questions concerning tyrosine kinase-inhibitor therapy and transplants in chronic phase chronic myeloid leukaemia;Leukemia;2022-03-25

2. Why chronic myeloid leukaemia cannot be cured by tyrosine kinase-inhibitors;Leukemia;2021-05-17

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3